Table 3. Likelihood of Severe Covid-19, According to Treatment with Various Antihypertensive Agents, in Propensity-Score–Matched Patients with a Positive Test for Covid-19, with Hypertension and Overall.*.
| Medication | Matched Patients with Hypertension | All Matched Patients | ||||
|---|---|---|---|---|---|---|
| Severe Covid-19 in Patients Treated with Medication |
Severe Covid-19 in Patients Not Treated with Medication |
Median Difference (95% CI) |
Severe Covid-19 in Patients Treated with Medication |
Severe Covid-19 in Patients Not Treated with Medication |
Median Difference (95% CI) |
|
| no./total no. (%) | percentage points | no./total no. (%) | percentage points | |||
| ACE inhibitor | 139/584 (23.8) | 158/583 (27.1) | −3.3 (−8.2 to 1.7) | 150/627 (23.9) | 169/653 (25.9) | −1.9 (−6.6 to 2.8) |
| ARB | 161/629 (25.6) | 156/612 (25.5) | 0.1 (−4.8 to 4.9) | 162/664 (24.4) | 165/639 (25.8) | −1.4 (−6.1 to 3.3) |
| ACE inhibitor or ARB | 252/1019 (24.7) | 249/986 (25.3) | −0.5 (−4.3 to 3.2) | 275/1110 (24.8) | 274/1101 (24.9) | −0.1 (−3.7 to 3.5) |
| Beta-blocker | 210/792 (26.5) | 231/829 (27.9) | −1.4 (−5.7 to 3.0) | 230/912 (25.2) | 250/976 (25.6) | −0.4 (−4.3 to 3.6) |
| Calcium-channel blocker | 253/950 (26.6) | 207/930 (22.3) | 4.4 (0.5 to 8.2) | 263/992 (26.5) | 235/976 (24.1) | 2.4 (−1.4 to 6.2) |
| Thiazide diuretic | 116/515 (22.5) | 114/520 (21.9) | 0.6 (−4.5 to 5.7) | 120/549 (21.9) | 149/590 (25.3) | −3.4 (−8.3 to 1.6) |
*
Severe Covid-19 was defined as admission to the intensive care unit, the use of noninvasive or invasive mechanical ventilation, or death.